Longeveron Inc. (LGVN)
NASDAQ: LGVN · IEX Real-Time Price · USD
1.88
-0.07 (-3.59%)
At close: Nov 27, 2023, 4:00 PM
1.98
+0.10 (5.32%)
After-hours: Nov 27, 2023, 4:53 PM EST
Longeveron Revenue
Longeveron had revenue of $767.00K in the twelve months ending September 30, 2023, down -41.45% year-over-year. Revenue in the quarter ending September 30, 2023 was $150.00K, a -43.40% decrease year-over-year. In the year 2022, Longeveron had annual revenue of $1.22M, a decrease of -6.43%.
Revenue (ttm)
$767.00K
Revenue Growth
-41.45%
P/S Ratio
58.22
Revenue / Employee
$40,368
Employees
19
Market Cap
44.65M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2022 | 1.22M | -84.00K | -6.43% |
| Dec 31, 2021 | 1.31M | -4.32M | -76.80% |
| Dec 31, 2020 | 5.63M | -10.47K | -0.19% |
| Dec 31, 2019 | 5.64M | 3.50M | 164.17% |
| Dec 31, 2018 | 2.13M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Cue Health | 198.92M |
| FibroGen | 154.98M |
| Rapid Micro Biosystems | 20.56M |
| ReWalk Robotics | 9.15M |
| Matinas BioPharma Holdings | 4.28M |
| SAB Biotherapeutics | 4.09M |
| Aeglea BioTherapeutics | 1.05M |
| eFFECTOR Therapeutics | 675.00K |
LGVN News
- 16 days ago - Long-term Survival Data from Longeveron's ELPIS 1 Trial Presented at the 2023 Scientific Sessions of the American Heart Association - GlobeNewsWire
- 17 days ago - Longeveron Reports Third Quarter 2023 Results and Provides Corporate Update - GlobeNewsWire
- 24 days ago - Longeveron to Report Third Quarter 2023 Results and Provide Corporate Update on November 10, 2023 - GlobeNewsWire
- 4 weeks ago - Longeveron Inc. Featured in Syndicated Broadcast Highlighting Top-Line Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ for the Treatment of Mild Alzheimer's - GlobeNewsWire
- 6 weeks ago - Longeveron Announces Closing of $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 6 weeks ago - Longeveron Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - GlobeNewsWire
- 7 weeks ago - Longeveron stock jumps on Alzheimer's trial results - Market Watch
- 7 weeks ago - Longeveron Announces Positive Top-Line Results for Lomecel-B™ in its CLEAR MIND Phase 2a Clinical Trial in the Treatment of Mild Alzheimer's Disease - GlobeNewsWire